Articles by Daniel Marsh
Above Food Ingredients Shares Surge 22% Amid Delayed Filing
Above Food Ingredients shares soared 22% to $0.65 in heavy trading Monday, as the company's fiscal 2025 annual report remains delayed due to ongoing audit issues.
Celcuity Surges 16% on Promising Breast Cancer Drug Data
Celcuity shares jumped 16% after its lead drug candidate, gedatolisib, met the primary endpoint in a Phase 3 breast cancer trial for PIK3CA-mutant tumors, setting the stage for a supplemental FDA filing.
MNDR Surges After $119M Hector Capital Pact for BIMA, M&M Helix Buys
Mobile-health Network Solutions shares surged about 60% following a non-binding $119 million framework with Hector Capital to fund acquisitions of BIMA and M&M Helix.
Skycorp Solar Surges on $20.2M Deal, Dilution Risks Loom
Skycorp Solar shares surged 88.8% after announcing a $20.2M stock-funded acquisition of Nanjing Cesun Power and a $3M private placement, raising dilution concerns.
Destiny Tech100 Soars on AI and SpaceX Hype
Destiny Tech100 shares jumped 13.4% Monday, driven by demand for its private tech holdings like SpaceX and AI firms. The fund trades at nearly double its NAV.
Elong Power Surges 72% After Lock-Up Expiry, Supply Overhang Looms
Elong Power shares surged 72% after a lock-up on 4.2 million shares expired. The company faces supply concerns and a going-concern warning.
Dow Plunges 450 Points as Strait of Hormuz Tensions Fuel Oil Surge
The Dow dropped nearly 450 points Monday as oil surged 5% on Strait of Hormuz tensions. Amazon's logistics expansion hit UPS and FedEx, while GameStop launched a $56B bid for eBay.
Amazon Opens Logistics Network to All Businesses, FedEx Shares Slide 9%
Amazon's new supply chain service, opening its logistics network to all businesses, sent FedEx shares down 9% and UPS down nearly 10%.
Walmart vs Costco: Ad Revenue Surge Reshapes Retail Stock Battle
Walmart's ad business surges 46% to $6.4B, while Costco's membership renewals stay above 89%. The stock fight highlights shifting profit engines.
Clene Soars on FDA Nod for Accelerated ALS Drug Submission
Clene shares jumped after FDA feedback suggested its ALS drug data could support an accelerated approval filing. The company plans to submit in Q3 2026.